The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What clinical trials look at molecular relapse?
Gail Roboz
November 11, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia who is based at Weill Cornell Medicine, New York, US. We asked, "Are there any clinical trials focusing on molecular relapses and treatment?" In this video, Gail describes what a molecular relapse is, and explains that although there are no specific drugs to target molecular relapse, there are ongoing trials into treating relapse in specific molecular diseases such as NMP1-mutated and core binding factor acute myeloid leukemia.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
